long intergenic non-protein coding RNA 2254Genealiases: []
Q-omics provides the consensus-scored LINC02254 profile across patient tissues and cancer cell-line models. LINC02254 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, LINC02254 is differentially expressed in 8, with the highest sampling consensus in COAD. Additionally, LINC02254 RNA expression shows 13,065 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight UCS, COAD, and THYM as cancer lineages where LINC02254 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC02254 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC02254 survival associations across molecular data types. LINC02254 RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC02254 RNA expression–survival associations across cancer types. High LINC02254 expression shows unfavorable associations in KIRC, KICH, ACC and LIHC, but favorable associations in UCS and READ. The UCS Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify UCS as the clearest survival context for LINC02254 RNA expression.
This table summarizes LINC02254 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for LINC02254. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC02254 shows lower tumor expression in BRCA and THCA and higher tumor expression in COAD, STAD, LUSC and ESCA. The COAD box plot shows higher LINC02254 RNA expression in tumor versus normal tissue (log2 FC = +0.222, t-test p < 0.001).
This table shows molecular features associated with LINC02254 in patient tissues and cancer cell lines. In patient samples, LINC02254 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
